[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platinum-sensitive-recurrent-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platinum-sensitive-recurrent-ovarian-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100656254","phase-3-phase-iii-study-of-hs-20089-with-bevacizumab-in-platinum-sensitive-recurrent-ovarian-cancer-100656254",false,"NCT07821606","Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer","An Open-label, Multicentre, Randomized, Controlled Phase III Clinical Trial Comparing HS-20089 Plus Bevacizumab Versus Investigator's Choice of Platinum-based Chemotherapy Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer","HS-20089 PSOC","Inclusion Criteria:\n\n\\-\n\nThe main criteria are as follows:\n\n1. Female, aged 18 years or older (≥18 years)\n2. Willing to voluntarily participate in this clinical trial, understand the study procedures, and able to provide written informed consent\n3. Platinum-sensitive recurrence\n4. ECOG PS: 0-1\n5. Expected survival of more than 12 weeks.\n6. Women of childbearing potential must be willing to use appropriate contraceptive measures from the time of signing informed consent until 6 months after the last dose administration and should not be breastfeeding.\n7. Must be able to provide sufficient fresh or archived tumor tissue specimens that meet the requirements.\n\nExclusion Criteria:\n\n* 1\\. Prior treatment with topoisomerase I inhibitors; cytotoxic chemotherapy agents; small molecule inhibitors; antibody-drug conjugates (ADCs).\n\n  2\\. Prior major surgery within 4 weeks prior to radonmization. 3. Residual toxicity from previous treatments graded ≥ Grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.\n\n  4\\. History of a second primary malignancy. 5. Pleural effusion\u002Fascites requiring clinical intervention); presence of pericardial effusion.\n\n  6\\. Imaging evidence of bowel obstruction or symptoms\u002Fsigns suggestive of bowel obstruction.\n\n  7 History of gastrointestinal perforation or fistula, or any grade of intra-abdominal abcess within 3 months prior to randonmization.\n\n  8 Participants known to have central nervous system (CNS) metastases and\u002For carcinomatous meningitis, either previously diagnosed or identified during screening.\n\n  9 Severe or poorly controlled hypertension. 10 Clinically significant bleeding symptoms 11 History of severe arterial\u002Fvenous thromboembolic events 12. Clinically significant active viral, bacterial, or fungal infections requiring intravenous or oral pharmacological treatment 13. Known presence of an active infectious disease 14. History of interstitial lung disease of any grade","FEMALE","18 Years",{"count":20,"type":21},460,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a Phase III study evaluating the efficacy of HS-20089 in combination with bevacizumab versus investigator's choice of platinum-based chemotherapy in combination with bevacizumab in participants with platinum-sensitive recurrent ovarian cancer (PSOC).",[27],"Platinum-sensitive Recurrent Ovarian Cancer","NOT_YET_RECRUITING","2026-09-09",{"date":31,"type":32},"2026-09-16","ACTUAL",{"date":34,"type":21},"2026-11-01",{"date":36,"type":21},"2031-12-30",{"name":38,"class":39},"Hansoh BioMedical R&D Company","INDUSTRY",39]